Savant Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Savant Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,000	Closed	-$33K	–	269
2017 Q1	$33K	Buy	+1,000	New	+$25.5K	0.01%	259

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Savant Capital's RIGL Position: Q2 2017 in Review

Savant Capital sold out of Rigel Pharmaceuticals (RIGL) in Q2 2017, closing a stake of 1,000 shares — an estimated $33K sold.

Savant Capital first reported a position in RIGL in Q1 2017 and held it in 1 quarter. The position peaked at $33K in Q1 2017. 110 funds tracked by Wall St. Rank hold RIGL as of Q2 2017.

Savant Capital reported no remaining Rigel Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Savant Capital sold 1,000 Rigel Pharmaceuticals shares in Q2 2017, an estimated $33K.
Savant Capital first reported a position in Rigel Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Savant Capital's Rigel Pharmaceuticals position peaked at $33K in Q1 2017.
110 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2017.

Based on Savant Capital's 13F filing for Q2 2017, filed 3 Aug 2017.